The shareholders of BioInvent International AB (publ), reg no 556537-7263, are hereby invited to attend the extraordinary general meeting (the "EGM"), to be held at 10.30 a.m. Friday 9 March 2012 at the company's premises at the address Sölvegatan 41 in Lund, Sweden.

A.             NOTICE OF ATTENDANCE

Shareholders who wish to attend the EGM must:

(i)       be recorded in the printout of the share register maintained by Euroclear Sweden AB ("Euroclear"), as of Saturday 3 March 2012, and

(ii)      notify the company of their intention to attend the meeting at the address Sölvegatan 41, SE-223 70 Lund, Sweden, att: Marie Serwe, by telefax +46 462110806 or by telephone +46 46 286 85 50, or by e-mail [email protected], at 4 p.m., Monday 5 March 2012 at the latest.

In order to participate in the proceedings at the EGM, shareholders with nominee-registered shares must request the bank or broker to have the shares temporarily owner-registered with Euroclear. Such registration must be made as per Friday 2 March, 2012 and the bank or broker should therefore be notified in due time before said date.

On giving notice of attendance, the shareholder shall state name, personal identity number/registration number, number of shares held, phone number and, if applicable, the name of the representative. Proxy to act on behalf of a shareholder should be sent together with the notice of attendance. Representative of a legal person shall hand in a copy of a registration certificate or similar papers of authorisation. The company will supply proxy forms upon request from a shareholder.

B.             AGENDA FOR THE MEETING

Proposal for agenda

1.              Opening of the Meeting.
2.              Election of Chairman of the Meeting.
3.              Preparation and approval of the voting list.
4.              Election of persons to check the minutes.
5.              Determination of compliance with the rules of convocation.
6.              Approval of the agenda.
7.              Approval of the Board of Director's resolution to issue new shares with preferential right for the shareholders of the company.
8.              Closing of the meeting.

Proposal for the approval of the resolution of the Board of Directors to issue new shares with preferential right for the shareholders of the company (item 7)

On Monday 13 February 2012, the Board of Directors resolved, subject to the approval of the general meeting, to issue new shares with preferential right for the shareholders of the company on the following main terms.

The company's share capital shall be increased by at maximum SEK 3,360,262.50 by the issue of maximum 6,720,525 new shares. The company's shareholders shall have preferential right to subscribe for the new shares in proportion to the shares previously owned, whereby 10 existing shares shall entitle to subscription for one new share. The new shares are issued at a subscription price of SEK 15.60. The record date for determining which shareholders shall be entitled to subscribe for new shares with preferential right shall be 14 March 2012. Subscription for the new shares shall take place during the period as from 16 March 2012 up to and including 30 March 2012.

The Board of Directors proposes that the general meeting approves the resolution of the Board of Directors.

C.             SHAREHOLDERS RIGHT TO ASK QUESTIONS

At the EGM shareholders have the right to ask questions concerning the company, the company's financial position and matters and proposals to be dealt with at the meeting.

D.             AVAILABLE DOCUMENTS ETC

The Board of Directors full resolution on a new share issue and documents presented according to the Swedish Companies Act in connection herewith will be available at the company's office and will be distributed to shareholders who so request and state their postal address. The documents will also be available on the company's website www.bioinvent.se.

The total number of shares and votes in the company amounts to 67,205,257.

Lund in February 2012
The Board of Directors
  -- END -

To the editors:

About BioInvent
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based

pharmaceutical company that focuses on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences, Roche and ThromboGenics.

The company's competitive position is underpinned by an in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe, Servier, UCB and XOMA. More information is available at www.bioinvent.com.

For further information, please contact:

BioInvent International AB

Svein Mathisen                                                     Sten Westerberg
President & CEO                                                  Vice President, Investor Relations
Mobile: +46 (0)708-97 82 13                              Mobile: +46 (0)768-68 50 09
E-mail: [email protected]          E-mail: [email protected]

BioInvent International AB (publ)
Co. reg. No. 556537-7263,
Address: Sölvegatan 41
Mailing address: SE-223 70 LUND
Tel: +46 (0)46 286 85 50
[email protected]
www.bioinvent.com

Legal disclaimer

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act. The information was submitted for publication at 8.50 a.m. CET, on 14 February, 2012.